| Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion. | |
| | |
MedLine Citation:
|
PMID: 15229387 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin II, via AT1 receptors plays a key role in endothelial dysfunction and therefore, in atherogenesis. In order to assess whether long-term blockade of these receptors improve peripheral and coronary endothelial function, 13 patients were treated by candesartan cilexetil (AT2B, 16 mg/d in 10 patients and 8 mg in 3). Flow-mediated dilation (FMD, measured with ultra-sound technique) in the brachial artery and cold pressor testing (CPT)-induced changes in myocardial blood flow (MBF, measured with positron emission tomography) were assessed before and after a 6 month treatment period. AT2B did not alter FMD: 5.0 +/- 1.2% vs. 6.4 +/- 0.9% after treatment. MBF increased significantly during CPT before and after AT2B. Although AT2B did not significantly modify heart rate and blood pressure, MBF normalized to the rate pressure product (MBF/RPP x 10000) was significantly higher and this change remained significant during CPT: it increased from 0.94 +/- 0.05 ml/g/min to 1.14 +/- 0.09 ml/g/min after AT2B (P < .05) and did not decrease during CPT (1.12 +/- 0.08 ml/g/min). Moreover, these AT2B-induced changes in normalized MBF were significantly correlated with the changes in FMD (r = 0.66, P < 0.05). Thus, long-term AT2B improves coronary vasomotion. Although no significant alteration in peripheral conduit endothelial function has been observed, treatment-induced FMD changes seem to be a predictor of coronary circulation improvement. |
| | |
Authors:
|
Nicolas Preumont; Philippe Unger; Serge Goldman; Guy Berkenboom |
Related Documents
:
|
21401347 - Symmetrical ambulatory arterial stiffness index: relationship with serum cystatin c lev... 130207 - Effect of intramyocardial pressure on the phasic flow in the intraventricular septal ar... 11100937 - Effect of angiotensin inhibition on the coronary artery lower pressure limit in anesthe... 21124327 - How many measurements are needed to provide reliable information in terms of the ambula... 15711977 - Noninvasive positive pressure ventilation in infants with upper airway obstruction: com... 6379137 - Combined high-frequency oscillatory ventilation and intermittent mandatory ventilation ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy Volume: 18 ISSN: 0920-3206 ISO Abbreviation: Cardiovasc Drugs Ther Publication Date: 2004 May |
Date Detail:
|
Created Date: 2004-07-01 Completed Date: 2004-12-03 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8712220 Medline TA: Cardiovasc Drugs Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 197-202 Citation Subset: IM |
Affiliation:
|
Erasme Hospital, Department of Cardiology, Route de Lennik 808, B-1070, Brussels, Belgium. nicolas@preumont.be |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Angiotensin II Type 1 Receptor Blockers / administration & dosage, pharmacology, therapeutic use* Belgium Benzimidazoles / administration & dosage, pharmacology, therapeutic use Biphenyl Compounds / administration & dosage, pharmacology, therapeutic use Blood Pressure / drug effects, physiology Brachial Artery / drug effects, physiology Cold Temperature / diagnostic use Coronary Artery Disease / diagnosis, drug therapy Coronary Stenosis / diagnosis, drug therapy Coronary Vessels / drug effects*, physiopathology Drug Administration Schedule* Endothelium, Vascular / drug effects, physiology Female Follow-Up Studies Heart Rate / drug effects, physiology Humans Hyperemia / chemically induced Individuality Male Patient Selection Pharmacology, Clinical / methods Positron-Emission Tomography / methods Regional Blood Flow / drug effects, physiology Tetrazoles / administration & dosage, pharmacology, therapeutic use Time Factors Ultrasonography / methods Vasodilation / drug effects Vasomotor System / drug effects*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Tetrazoles; 145040-37-5/candesartan cilexetil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Roles of systemic nitric oxide metabolites for human coronary circulation.
Next Document: Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients wi...